FDA Approves Boston Scientific's Next-Generation TAXUS R Liberte R Atom TM Stent Operation
/* 468x60, */
Boston Scientific Corporation (NYSE: BSX) announced it has received approval from the U.S. Comestible and Narcotic State (FDA) to its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for apply in vessels as miniature as 2.25 mm in calibre and joins the TAXUS(R) Express(R) Atom(TM) Stent as the only drug-eluting stents approved for small vessel end in the U.S. The Business plans to launch a abundant U.S. launch of TAXUS Liberte Atom next month.
"The close adoption of the TAXUS Express Atom Stent has confirmed the need for this type of stenting option in the treatment of small-vessel coronary artery disease," said Objective Turco, M.D., F.A.C.C., F.S.C.A.I., Employer of the Center for Cardiac and Vascular Probation at Washington Adventist Hospital, Takoma Park, Maryland. "The TAXUS Liberte Atom Stent provides free of charge draft and deliverability advantages. Additionally, in the TAXUS Atlas Petite Vessel clinical trial, the TAXUS Liberte Atom Stent yielded a two-year protest lesion revascularization standard that was 60 percent less than the TAXUS Explicit Atom Stent. I am satisfied to be able to offer this option to my patients."
Data from heaps clinical studies annex shown that an estimated 10 percent of patients undergoing percutaneous coronary interventions have little vessels (<2.5 mm). Until recently, distinct physicians were inclined to implant bare-metal stents in these patients owing to they were the solitary approved stenting possibility for small vessels. Behind year's commence of the TAXUS Express Atom Stent offered an alternative treatment choice for patients with diminutive vessels who testament immediately have the more preference of the TAXUS Liberte Atom Stent.
The TAXUS Liberte Stent features design improvements over the Company's first-generation TAXUS Clear-cut Stent, including thinner struts to permit more select stent deliverability and conformability, as blooming as uniform stent geometry for consistent lesion coverage and drug distribution.
Boston Scientific offers the industry's widest scale of coronary stent sizes. The Partnership expects to expand its stent portfolio later this year with the headmost 38 mm long DES, the TAXUS(R) Liberte(R) Extended Stent, which is currently under review with the FDA.
TAXUS Stents posses been evaluated by the industry's most spread out randomized, controlled clinical check program, with follow-up to five senility in some cases. These probation results have been supplemented by data on more than 35,000 patients enrolled in post-approval registries. To date, on all sides of 11 million Boston Scientific stents admit been implanted globally, making them the world's most often used stents.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad scope of interventional medical specialties
TAXUS Stents accept been evaluated by the industry's most extensive randomized, controlled clinical trial program, with follow-up to five agedness in some cases. These trial results have been supplemented by facts on more than 35,000 patients enrolled in post-approval registries. To date, encircling 11 million Boston Scientific stents have been implanted globally, making them the world's most frequently used stents.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a wide reach of interventional medical specialties.
Cautionary Statement Regarding Forward-Looking Statements
This press proceeds contains forward-looking statements within the meaning of Incision 21E of the Securities Alter Fact of 1934. Forward-looking statements may be identified by paragraph like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance, competitive offerings, procedural volume, overall marketplace extent and our mart position. Whether our underlying assumptions turn outside to be incorrect, or provided persuaded risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, acquire affected and in the booked (together with other factors) could impinge our dexterity to contrivance our affair strategy and may explanation actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may element such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; mental property; litigation; financial bazaar conditions; and, future event decisions trumped-up by us and our competitors. All of these factors are difficult or impossible to predict accurately and diverse of them are beyond our control. For a very record and discription of these and other important risks and uncertainties that may inspire our future operations, gaze Constituent I, Protest 1A - Risk Factors in our most contemporary Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Object 1A - Risk Factors in Quarterly Reports on Form 10-Q we retain filed or will file thereafter. We disclaim any rationale or obligation to publicly update or revise any forward-looking statements to reply any quarters in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may interest the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is relevant to all forward-looking statements contained in this document.
Source: Boston Scientific Society
/* 468x60, */
Last relative articles:
- Use Of Statins Increases The Risk Of Developing Type 2 Diabetes But Reduces Coronary Events
- Heart Failure Worse When Right Ventricle Goes Bad
- Cooling Inflammation For Healthier Arteries
- Experts Identify Why Women And African Americans Face A Greater Risk Of Dying From Heart Disease Than White Men And What Can Be Done About It
- New Book Helps Pharmacists Play Larger Role In Heart Health
- Novel Screening Technique Identifies New Effects Of Approved Drugs For Cardiovascular Disease
- Compound Shows Promise Against Intractable Heart Failure
- Researchers Find Air Pollution Linked To Progression Of Atherosclerosis
- Heart-Assist Device Helped Ready 16-Year-Old For Successful Surgery
- Seven Signs That May Warn Of A Rare Heart Condition
stent, atom stent, tm stent, stent operation, coronary stent, stent taxus, stent offered, stent sizes, stent portfolio, stent des